Endothelial cells, fibroblasts and vasculitis

Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol1995;57:827–72.

Hirschi KK, D'Amore PA. Pericytes in the microvasculature. Cardiovasc Res1996;32:687–98.

Ahmad SA, Jung YD, Liu W et al. The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. Semin Cancer Biology2002;12:105–12.

Muller WA. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol2003;24:327–34.

Alon R, Feigelson S. From rolling to arrest on blood vessels: leukocyte tap dancing on endothelial integrin ligands and chemokines at sub-second contacts. Semin Immunol2002;14:93–104.

Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity2002;16:1–4.

Yadav R, Larbi KY, Young RE et al. Migration of leukocytes through the vessel wall and beyond. Thromb Haemost2003;90:598–606.

Chi JT, Chang HY, Haraldsen G et al. Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci USA2003;100:10623–8.

Dai G, Kaazempur-Mofrad MR, Natarajan S et al. Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature. Proc Natl Acad Sci USA2004;101:14871–6.

Choi J, Enis DR, Koh KP et al. T lymphocyte-endothelial cell interactions. Annu Rev Immunol2004;22:683–709.

Nash GB, Buckley CD, Rainger GE. The local physicochemical environment conditions the proinflammatory response of endothelial cells and thus modulates leukocyte recruitment. FEBS Lett2004;569:13–7.

Bergers G, Song S, Meyer-Morse N et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest2003;111:1287–95.

Rainger GE, Nash GB. Cellular pathology of atherosclerosis: smooth muscle cells prime cocultured endothelial cells for enhanced leukocyte adhesion. Circ Res2001;88:615–22.

Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature2004;432:332–7.

Dong J, Grunstein J, Tejada M et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J2004;23:2800–10.

Buckley CD, Pilling D, Lord JM et al. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol2001;22:199–204.

Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation2004;109:II27–33.

Hingorani AD, Cross J, Kharbanda RK et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation2000;102:994–9.

Raza K, Thambyrajah J, Townend JN et al. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease? Circulation2000;102:1470–2.

Filer AD, Gardner-Medwin JM, Thambyrajah J et al. Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann Rheum Dis2003;62:162–7.

Booth AD, Wallace S, McEniery CM et al. Inflammation and arterial stiffness in systemic vasculitis: A model of vascular inflammation. Arthritis Rheum2004;50:581–8.

Booth AD, Jayne DR, Kharbanda RK et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation2004;109:1718–23.

Wimalasundera R, Fexby S, Regan L et al. Effect of tumour necrosis factor-alpha and interleukin 1beta on endothelium-dependent relaxation in rat mesenteric resistance arteries in vitro. Br J Pharmacol2003;138:1285–94.

Chia S, Qadan M, Newton R et al. Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol2003;23:695–701.

Stevens RJ, Gardner-Medwin JM, Carruthers DM et al. Endothelial dysfunction improves acutely after infliximab. Rheumatology2002;41:24.

Anderson HD, Rahmutula D, Gardner DG. Tumor necrosis factor-alpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. J Biol Chem2004;279:963–9.

Lai PF, Mohamed F, Monge JC et al. Downregulation of eNOS mRNA expression by TNFalpha: identification and functional characterization of RNA–protein interactions in the 3′UTR. Cardiovasc Res2003;59:160–8.

Corda S, Laplace C, Vicaut E et al. Rapid reactive oxygen species production by mitochondria in endothelial cells exposed to tumor necrosis factor-alpha is mediated by ceramide. Am J Respir Cell Mol Biol2001;24:762–8.

Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation1997;96:3042–7.

Venugopal SK, Devaraj S, Yuhanna I et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation2002;106:1439–41.

Verma S, Wang CH, Li SH et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation2002;106:913–9.

Venugopal SK, Devaraj S, Jialal I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation2003;108:1676–8.

Paul A, Ko KW, Li L et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation2004;109:647–55.

Hsueh WA, Lyon CJ, Quinones MJ. Insulin resistance and the endothelium. Am J Med2004;117:109–17.

Sattar N, McCarey DW, Capell H et al. Explaining how ‘high-grade’ systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation2003;108:2957–63.

Hurlimann D, Forster A, Noll G et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation2002;106:2184–7.

Gonzalez-Juanatey C, Testa A, Garcia-Castelo A et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med2003;114:647–52.

El Magadmi M, Bodill H, Ahmad Y et al. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation2004;110:399–404.

Banks M, Flint J, Bacon PA, Kitas GD. Rheumatoid arthritis is an independent risk factor for ischaemic heart disease. Arthritis Rheum2000;43:385.

del Rincon ID, Williams K, Stern MP et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum2001;44:2737–45.

Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol1997;145:408–15.

Zaenker M, Aries PM, Herlyn K et al. Accelerated atherosclerosis in Wegener's granulomatosis (WG): a sonographic case-control study on intima media thickness. Arthritis Rheum2002;46:S185.

Salisbury EM, McLaren JS, Jayne DRW et al. Cardiovascular and cerebrovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis. Rheumatology2004;43:ii9.